La Jolla Pharmaceutical Company (LJPC) news stock charts
La Jolla Pharmaceutical Company (LJPC) Investment Summary:
La Jolla Pharmaceutical Company was incorporated in Delaware in 1989. In October 2004 the Company established a subsidiary, La Jolla Limited, which was organized in England in connection with the potential development efforts for Riquent in Europe. We are a biopharmaceutical company focused on the research and development of highly specific therapeutic products for the treatment of certain life-threatening antibody-mediated diseases. These diseases, including autoimmune conditions such as lupus, are caused by abnormal B cell production of antibodies that attack healthy tissues. Current treatments for these autoimmune disorders often address only symptoms of the disease, or nonspecifically suppress the normal operation of the immune system, which can result in severe, negative side effects and hospitalization. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2005%2f03%2f10%2f0000950137-05-002829.html#FIS_BUSINESS"LA JOLLA PHARMACEUTICAL CO (LJPC:Pink OTC Markets Inc)
Snapshot of LA JOLLA PHARMACEUTICAL CO (LJPC)
|
OPEN
$0.09
|
PREVIOUS CLOSE
$0.09
|
|
|
DAY HIGH
$0.09
|
DAY LOW
$0.07
|
|
|
52 WEEK HIGH
05/8/09 - $0.64
|
52 WEEK LOW
11/19/09 - $0.06
|
|
|
MARKET CAP
4.9M
|
AVERAGE VOLUME 10 D
1.4M
|
|
|
EPS TTM
$-0.38
|
SHARES OUTSTANDING
65.7M
|
|
|
LJPC Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Key developments for LA JOLLA PHARMACEUTICAL CO (LJPC)
La Jolla Pharmaceutical Company announced that it received notification from the NASDAQ Hearings Panel that the Panel has determined to deny the Companys request for continued listing on The NASDAQ Stock Market and that trading of the Company's common stock will be suspended effective at the open of business on March 4, 2010. The Panel determined that the Company is operating as a public shell because of the Companys nominal assets, other than cash, and the Companys nominal operations. The Company also announced that holders of only thirteen percent (13%) of La Jollas outstanding common stock returned their proxy cards or otherwise indicated their votes with respect to proposals related to its proposed merger with Adamis Pharmaceuticals Corporation, prior to the start of the stockholders meeting. As a result, there was no quorum to conduct the meeting. The meeting and the solicitation of further votes has been canceled due to the delisting from NASDAQ. The Company anticipates that its common stock will be quoted on the Pink OTC Markets Inc. automatically and immediately after NASDAQ suspends trading, provided that a market maker, who has quoted the Companys common stock in the 30 days prior to delisting, enters a quote on the Pink Sheets prior to market close on March 4, 2010. The Company's common stock may, in the future, also be quoted on the Over-the-Counter Bulletin Board. A Form 25-NSE will be filed with the Securities and Exchange Commission to remove the Companys securities from listing and registration on NASDAQ.
La Jolla Pharmaceutical Co., Special/Extraordinary Shareholders Meeting, Mar 02, 2010, at 15:00 US Pacific Time. Agenda: To propose merger with Adamis Pharmaceuticals Corporation .
On January 19, 2010, La Jolla Pharmaceutical Co. received a notice (the Notice) from the NASDAQ Stock Market indicating that NASDAQ believes that the Company is operating as a public shell and that the resulting entity in the proposed merger between the Company and Adamis Pharmaceuticals Corporation (Adamis) will not meet NASDAQs initial listing requirements. NASDAQ has determined that public shells could be detrimental to the interests of the investing public. Listing Rule 5101 provides NASDAQ with discretionary authority to apply more stringent criteria for continued listing and terminate the inclusion of particular securities based on any event that occurs that in the opinion of NASDAQ makes inclusion of the securities on NASDAQ inadvisable or unwarranted. The Company intends to appeal the determination in the January 19 letter. Absent such an appeal, trading of the Companys common stock would be suspended at the open of business on January 28, 2010 and a Form 25-NSE would be filed with the Securities and Exchange Commission to remove the Companys securities from listing and registration on NASDAQ. The Companys appeal will stay the suspension of the trading of the Companys common stock pending a final decision by a NASDAQ Listing Qualifications Panel. The Company must submit its request for a hearing no later than January 26, 2010. Notwithstanding the appeal, the Company expects that its stock will be delisted following the completion of the merger with Adamis as the transaction will constitute a change of control and the combined entity is not expected to satisfy the NASDAQ initial listing standards that would be applied at that time.
La Jolla Pharmaceutical Company financial resources
LJPC Competitors
| Company | Last | Change | |
| No competitor information is available for LJPC. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | LJPC | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 0.7x |
|
| Price/Book | 1.0x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
LJPC |
||
LJPC transactions
| Type Date |
Target |
|
Merger/Acquisition
October 16, 2009 |
-- |
More Recent Financial News About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company Provides Voting Update - More Votes Needed or La Jolla Will Likely Close
Read article
La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders
Read article
La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders
Read article
LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Read article
LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Read article
La Jolla Pharmaceutical Company Provides Voting Update - More Votes Needed or La Jolla Will Likely Close
Read article
LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Read article
LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Read article
La Jolla Pharmaceutical Company Receives Nasdaq Delisting Notice and Intends to Appeal Determination
Read article
Emerging Stock Report Initiates Independent Research Coverage on La Jolla Pharmaceutical Company (LJPC)
Read article
Stock Watch: InvestorSoup.com issues Market Alert for La Jolla Pharmaceuticals Co.
Read article
La Jolla Pharmaceutical Company Announces Filing of Joint Proxy Statement/Prospectus
Read article
LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Read article
La Jolla Pharmaceutical Company Receives Nasdaq Delisting Notice and Intends to Appeal Determination
Read article
Biotech Stock Alert for La Jolla Pharmaceutical Co. Issued by StockPreacher
Read article
Biotech Stock Alert for La Jolla Pharmaceutical Co. Issued by StockPreacher
Read article
La Jolla Pharmaceutical Company Announces Filing of Joint Proxy Statement/Prospectus
Read article
LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events
Read article
Stock Watch: InvestorSoup.com Issues Market Alert for La Jolla Pharmaceuticals Co.
Read article
LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pri
Read article